BOSTON --(BUSINESS WIRE)--Nov. 30, 2022-- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of

BOSTON --(BUSINESS WIRE)--Nov. 30, 2022-- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of

Announced the Global Phase 3 Trial Design with Suprachoroidal Route of Administration of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma First Patient Dosed in the Phase 1 Study Evaluating Belzupacap Sarotalocan for the Treatment of Non-Muscle Invasive Bladder Cancer BOSTON --(BUSINESS

BOSTON --(BUSINESS WIRE)--Nov. 10, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that it has initiated startup activities for the global

BOSTON --(BUSINESS WIRE)--Nov. 3, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will participate in the

Aura to Host Virtual Investor Day at 11:30 a.m. Eastern Time BOSTON --(BUSINESS WIRE)--Oct. 3, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced

BOSTON --(BUSINESS WIRE)--Sep. 28, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been dosed in a Phase 1 study

Company to Host Virtual Investor Day with Ocular Oncology Experts on Monday, October 3, 2022 , at 11:30 a.m. Eastern Time BOSTON --(BUSINESS WIRE)--Sep. 27, 2022-- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 7, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Phase 2 data evaluating the safety of

On Track to Initiate Pivotal Trial in Early-Stage Choroidal Melanoma in Q4 2022 On Track to Submit IND in Choroidal Metastasis in 2H 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of